Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Pexidartinib

Aliases
PLX3397, TURALIO™
Name
Turalio
INN Name
pexidartinib hydrochloride
FDA Approved
Yes

3 clinical trials

1 organization

1 indication

1 document

Indication
Tenosynovial Giant Cell Tumor
Clinical trial
Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor
Status: Active (not recruiting), Estimated PCD: 2021-10-27
Clinical trial
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan
Status: Recruiting, Estimated PCD: 2025-02-28
Document
DailyMed Label: Turalio
Organization
Daiichi Sankyo, Inc.